Oncolytics Biotech Inc. (TSE:ONC - Get Free Report)'s share price rose 10.1% on Wednesday . The stock traded as high as C$0.99 and last traded at C$0.98. Approximately 142,896 shares changed hands during trading, an increase of 24% from the average daily volume of 115,398 shares. The stock had previously closed at C$0.89.
Analysts Set New Price Targets
Separately, Jones Trading cut Oncolytics Biotech from a "strong-buy" rating to a "hold" rating in a research note on Friday, May 16th.
Read Our Latest Research Report on ONC
Oncolytics Biotech Trading Down 1.0%
The business's 50 day moving average price is C$0.70 and its two-hundred day moving average price is C$0.94. The company has a debt-to-equity ratio of 11.75, a quick ratio of 8.86 and a current ratio of 2.99. The company has a market capitalization of C$73.99 million, a price-to-earnings ratio of -2.67 and a beta of 1.35.
Oncolytics Biotech Company Profile
(
Get Free Report)
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.
Read More
Before you consider Oncolytics Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oncolytics Biotech wasn't on the list.
While Oncolytics Biotech currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
